IQVIA vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest CRO and healthcare data company; $15.2B FY2024 revenue; 1B+ patient records; powers pharma R&D and commercial analytics; benefits from GLP-1 and oncology pipeline boom.
About
IQVIA Holdings is the world's largest contract research organization (CRO) and leading provider of healthcare data and analytics, formed in 2016 through the $9 billion merger of IMS Health (healthcare information and technology services) and Quintiles Transnational Holdings (clinical research services), headquartered in Durham, North Carolina and trading on NYSE (IQV). The company generated approximately $15.2 billion in revenues for FY2024 under CEO Ari Bousbib, who led both legacy companies and has driven the combined entity to become an indispensable partner to pharmaceutical and biotechnology companies across the drug development lifecycle—from clinical trial design and execution through regulatory approval and commercial launch analytics.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.